Search Results - "Bogman, Katrijn"

The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins by Bogman, Katrijn, Erne-Brand, Françoise, Alsenz, Jochem, Drewe, Jürgen

“…A variety of seven nonionic, one amphoteric and, one anionic surfactant that are applied or investigated as surfactants in drug formulation, were analyzed for…”
Get more information

HMG‐CoA reductase inhibitors and P‐glycoprotein modulation by Bogman, Katrijn, Peyer, Anne‐Kathrin, Török, Michael, Küsters, Ernst, Drewe, Jürgen

“…Five 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase inhibitors (statins), (e.g. atorvastatin, fluvastatin, lovastatin, pravastatin and simvastatin),…”
Get full text

Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients by Bogman, Katrijn, Silkey, Mariabeth, Chan, Siew Pheng, Tomlinson, Brian, Weber, Cornelia

“…Objectives R483 is a thiazolidinedione peroxisome proliferator-activated receptor gamma (PPARγ) agonist with anti-diabetic properties and also a cytochrome…”
Get full text

Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2) by Bogman, Katrijn, Schwab, Dietmar, Delporte, Marie-Laure, Palermo, Giuseppe, Amrein, Kurt, Mohr, Susanne, De Vera Mudry, Maria Cristina, Brown, Morris J, Ferber, Philippe

“…Primary hyperaldosteronism is a common cause of resistant hypertension. Aldosterone is produced in the adrenal by aldosterone synthase (AS, encoded by the gene…”
Get full text

Ocular Pharmacokinetics of Faricimab Following Intravitreal Administration in Patients With Retinal Disease by Diack, Cheikh, Gibiansky, Leonid, Jaminion, Felix, Gibiansky, Ekaterina, Gaudreault, Jacques, Bogman, Katrijn, Cosson, Valerie

“…To characterize faricimab ocular and systemic pharmacokinetics (PK) in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular…”
Get full text

Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies by Morcos, Peter N., Bogman, Katrijn, Hubeaux, Stanislas, Sturm-Pellanda, Carolina, Ruf, Thorsten, Bordogna, Walter, Golding, Sophie, Zeaiter, Ali, Abt, Markus, Balas, Bogdana

“…Purpose Alectinib, a central nervous system (CNS)-active ALK inhibitor, has demonstrated efficacy and safety in ALK + non-small-cell lung cancer that has…”
Get full text

Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects by Morcos, Peter N., Yu, Li, Bogman, Katrijn, Sato, Mika, Katsuki, Hisakazu, Kawashima, Kosuke, Moore, David J, Whayman, Matt, Nieforth, Keith, Heinig, Katja, Guerini, Elena, Muri, Dieter, Martin-Facklam, Meret, Phipps, Alex

“…1. Alectinib is a highly selective, central nervous system-active small molecule anaplastic lymphoma kinase inhibitor. 2. The absolute bioavailability,…”
Get full text

Assessment of Drug–Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials by Bogman, Katrijn, Brumm, Jochen, Hofmann, Carsten, Giraudon, Mylène, Niggli, Markus, Sturm-Pellanda, Carolina, Sauter, Annette, Sturm, Stefan, Mangold, Bernhard, Schmitt, Christophe

“…Background and Objective Taspoglutide, a glucagon-like peptide-1 agonist, like native glucagon-like peptide-1, delays gastric emptying time and prolongs…”
Get full text

CANBERRA, A Phase 2 Randomized Clinical Trial to Test the Therapeutic Potential of Oral Vicasinabin in Diabetic Retinopathy by Armendariz, Beatriz G., Luhman, Ulrich F.O., Berger, Brian, Sanchez, Jules Hernandez, Bogman, Katrijn, Mitrousis, Nikolaos, Wollenhaupt, Martina, Kent, David, Wenzel, Andreas, Fauser, Sascha

Get full text

Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema by Diack, Cheikh, Avery, Robert L., Cheung, Chui Ming Gemmy, Csaky, Karl G., Gibiansky, Leonid, Jaminion, Felix, Gibiansky, Ekaterina, Sickert, Denise, Stoilov, Ivo, Cosson, Valerie, Bogman, Katrijn

“…Evaluate the ocular pharmacodynamics (PD) of intravitreal faricimab, a bispecific inhibitor of angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A…”
Get full text

Effect of alectinib on cardiac electrophysiology: Results from intensive electrocardiogram (ECG) monitoring of alectinib phase I/II pivotal studies by Morcos, Peter N., Bogman, Katrijn, Henschel, Volkmar, Sturm, Carolina, Ruf, Thorsten, Bordogna, Walter, Golding, Sophie, Zeaiter, Ali Hassan, Balas, Bogdana

“…Abstract only…”
Get full text

Population pharmacokinetics (popPK) and exposure-response (ER) analyses to confirm alectinib 600 mg BID dose selection in a crizotinib-progressed or intolerant population by Hsu, Joy C., Carnac, Ronan, Henschel, Volkmar, Bogman, Katrijn, Martin-Facklam, Meret, Guerini, Elena, Balas, Bogdana, Zeaiter, Ali Hassan, Phipps, Alex, Morcos, Peter N., Frey, Nicolas

“…Abstract only…”
Get full text

Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects by Morcos, Peter N., Guerini, Elena, Parrott, Neil, Dall, Georgina, Blotner, Steven, Bogman, Katrijn, Sturm, Carolina, Balas, Bogdana, Martin‐Facklam, Meret, Phipps, Alex

“…Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, is approved for treatment of patients with ALK+ non–small cell lung cancer who have progressed, on or…”
Get full text

Clinical Drug–Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib by Morcos, Peter N., Cleary, Yumi, Guerini, Elena, Dall, Georgina, Bogman, Katrijn, Petris, Luigi, Viteri, Santiago, Bordogna, Walter, Yu, Li, Martin‐Facklam, Meret, Phipps, Alex

“…The efficacy and safety of alectinib, a central nervous system–active and selective anaplastic lymphoma kinase (ALK) inhibitor, has been demonstrated in…”
Get full text

P-Glycoprotein and Surfactants: Effect on Intestinal Talinolol Absorption by Bogman, Katrijn, Zysset, Yvonne, Degen, Lukas, Hopfgartner, Gérard, Gutmann, Heike, Alsenz, Jochem, Drewe, Juergen

“…Background and Objective Surfactants used in pharmaceutical formulations can modulate drug absorption by multiple mechanisms including inhibition of intestinal…”
Get full text

Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy Subjects by Morcos, Peter N., Parrott, Neil, Banken, Ludger, Timpe, Carsten, Lindenberg, Marc, Guerini, Elena, Dall, Georgina, Bogman, Katrijn, Sturm, Carolina, Zeaiter, Ali, Martin‐Facklam, Meret, Phipps, Alex

“…The anaplastic lymphoma kinase (ALK) inhibitor alectinib is an effective treatment for ALK‐positive non‐small‐cell lung cancer. This bioequivalence study…”
Get full text

Mechanisms of venoocclusive disease resulting from the combination of cyclophosphamide and roxithromycin by KAUFMANN, Priska, HASCHKE, Manuel, TÖRÖK, Michael, BELTINGER, Johannes, BOGMAN, Katrijn, WENK, Markus, TERRACCIANO, Luigi, KRÄHENBÜHL, Stephan

“…High doses (>or=500 mg/m) of cyclophosphamide are known to cause venoocclusive disease (VOD). The authors recently observed a patient treated with…”
Get full text